Cadila's stock rising: Credit Suisse

BSE 19 Jun 13 | 12:00 AM

793.50		14.4 (1.85%)
Mkt Price (Rs)		Chg Rs (Chg %)

Code: 532321

Face Value: N.A.

NSE 19 Jun 13 | 12:00 AM

792.95		14.8 (1.9%)
Mkt Price (Rs)		Chg Rs (Chg %)

Code: CADILAHC

Performance
1 Week	:	Rs	740.80	(7.11%)
1 Month	:	Rs	807.70	(-1.76%)
1 Year	:	Rs	743.70	(6.70%)

Cadila's stock rising: Credit Suisse

Reuters / 18 Jul 12 | 11:50 AM

Be the first to comment

Credit Suisse initiates coverage on Cadila Healthcare with an "outperform" rating and a target price of Rs 970.

Investment bank says the midcap drug maker has demonstrated "strong execution" in the United States, with a portfolio mix focusing on low competition products such as nasal sprays and injectable drugs.

USFDA approval of its facilities in Moraiya, part of Gujarat, will re-start new approvals of its drugs in the US market, Credit Suisse adds.

"Cadila is moving up the value-chain with the launch of difficult-to formulate products and its strong execution record provides multi-year growth visibility."